Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $15.00 at Craig Hallum

Eton Pharmaceuticals (NASDAQ:ETON - Free Report) had its target price hoisted by Craig Hallum from $10.00 to $15.00 in a research note published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright boosted their price target on shares of Eton Pharmaceuticals from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Friday, October 4th.

Eton Pharmaceuticals Trading Up 3.8 %

Eton Pharmaceuticals stock traded up $0.31 during midday trading on Monday, reaching $8.42. 391,200 shares of the stock traded hands, compared to its average volume of 84,906. The firm has a market cap of $217.57 million, a PE ratio of -32.38 and a beta of 1.31. The company has a 50-day simple moving average of $6.02 and a two-hundred day simple moving average of $4.39. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $8.66.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The business had revenue of $9.07 million during the quarter, compared to analysts' expectations of $10.00 million. Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. Equities research analysts anticipate that Eton Pharmaceuticals will post -0.17 earnings per share for the current year.

Insider Buying and Selling at Eton Pharmaceuticals

In other news, major shareholder Opaleye Management Inc. bought 16,852 shares of the business's stock in a transaction that occurred on Friday, October 4th. The shares were purchased at an average cost of $6.77 per share, for a total transaction of $114,088.04. Following the completion of the purchase, the insider now owns 2,720,000 shares of the company's stock, valued at approximately $18,414,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have purchased 85,600 shares of company stock valued at $462,674 in the last quarter. Corporate insiders own 14.89% of the company's stock.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Westside Investment Management Inc. increased its holdings in shares of Eton Pharmaceuticals by 1.9% in the 1st quarter. Westside Investment Management Inc. now owns 573,960 shares of the company's stock valued at $2,152,000 after acquiring an additional 10,850 shares during the last quarter. Acadian Asset Management LLC increased its stake in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company's stock valued at $585,000 after purchasing an additional 18,898 shares during the last quarter. Thompson Siegel & Walmsley LLC acquired a new stake in Eton Pharmaceuticals during the second quarter worth approximately $420,000. Renaissance Technologies LLC lifted its position in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock worth $350,000 after buying an additional 41,469 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at $3,095,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.